DrugPatentWatch Database Preview
Investigational Drug Information for Tetrahydrouridine
Email this page to a colleague
What is the drug development status for Tetrahydrouridine?
Tetrahydrouridine is an investigational drug.
There have been 17 clinical trials for Tetrahydrouridine.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2000.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Head and Neck Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), EpiDestiny, Inc., and Yogen Saunthararajah.
Summary for Tetrahydrouridine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 222 |
| WIPO Patent Applications | 127 |
| Japanese Patent Applications | 50 |
| Clinical Trial Progress | Phase 2 (2000-07-01) |
| Vendors | 31 |
Recent Clinical Trials for Tetrahydrouridine
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |
| A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | National Institutes of Health (NIH) | Phase 1 |
| A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease | EpiDestiny, Inc. | Phase 1 |
Clinical Trial Summary for Tetrahydrouridine
Top disease conditions for Tetrahydrouridine
Top clinical trial sponsors for Tetrahydrouridine
US Patents for Tetrahydrouridine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
